MIM
ALLO icon

MetLife Investment Management’s Allogene Therapeutics ALLO Stock Holding History

MetLife Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$180K Buy
73,717
+38,894
+112% +$78K ﹤0.01% 2281
2025
Q4 		$47.7K Sell
34,823
-22,434
-39% -$29.6K ﹤0.01% 2731
2025
Q3 		$71K Buy
+57,257
New +$68.3K ﹤0.01% 2760
2025
Q2 		– Sell
-79,823
Closed -$117K – 2764
2025
Q1 		$117K Buy
79,823
+41,803
+110% +$78.8K ﹤0.01% 2457
2024
Q4 		$81K Sell
38,020
-15,127
-28% -$37.3K ﹤0.01% 2688
2024
Q3 		$149K Sell
53,147
-5,993
-10% -$16K ﹤0.01% 2438
2024
Q2 		$138K Buy
59,140
+10,140
+21% +$29.9K ﹤0.01% 2453
2024
Q1 		$219K Buy
49,000
+6,982
+17% +$29.1K ﹤0.01% 2153
2023
Q4 		$135K Hold
42,018
– – ﹤0.01% 2456
2023
Q3 		$133K Hold
42,018
– – ﹤0.01% 2434
2023
Q2 		$209K Hold
42,018
– – ﹤0.01% 2252
2023
Q1 		$208K Hold
42,018
– – ﹤0.01% 2198
2022
Q4 		$264K Hold
42,018
– – ﹤0.01% 2070
2022
Q3 		$454K Buy
42,018
+1,668
+4% +$22.7K ﹤0.01% 1710
2022
Q2 		$460K Buy
40,350
+4,024
+11% +$35.7K ﹤0.01% 1723
2022
Q1 		$331K Buy
36,326
+13,419
+59% +$140K ﹤0.01% 2038
2021
Q4 		$342K Hold
22,907
– – ﹤0.01% 1724
2021
Q3 		$589K Hold
22,907
– – 0.01% 1439
2021
Q2 		$597K Hold
22,907
– – 0.01% 1466
2021
Q1 		$809K Hold
22,907
– – 0.01% 1261
2020
Q4 		$578K Hold
22,907
– – 0.01% 1416
2020
Q3 		$864K Buy
22,907
+1,351
+6% +$50.9K 0.01% 1101
2020
Q2 		$923K Buy
21,556
+3,547
+20% +$128K 0.01% 1071
2020
Q1 		$350K Hold
18,009
– – ﹤0.01% 1408
2019
Q4 		$468K Hold
18,009
– – ﹤0.01% 1505
2019
Q3 		$491K Hold
18,009
– – 0.01% 1432
2019
Q2 		$484K Buy
18,009
+5,373
+43% +$150K 0.01% 1497
2019
Q1 		$365K Hold
12,636
– – ﹤0.01% 1639
2018
Q4 		$340K Buy
+12,636
New +$336K ﹤0.01% 1600

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's ALLO Position: Q1 2026 in Review

MetLife Investment Management increased its Allogene Therapeutics (ALLO) stake by 112% in Q1 2026, buying an estimated $78K and bringing the position to 73,717 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #2281.

MetLife Investment Management first reported a position in ALLO in Q4 2018 and has held it in 29 quarters since. The position peaked at $923K in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • MetLife Investment Management held 73,717 shares of Allogene Therapeutics worth $180K as of Q1 2026.
  • MetLife Investment Management bought 38,894 Allogene Therapeutics shares in Q1 2026, an estimated $78K.
  • Allogene Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2281 holding.
  • MetLife Investment Management first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • MetLife Investment Management's Allogene Therapeutics position peaked at $923K in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.